ProCE Banner Activity

Casirivimab Plus Imdevimab: Monoclonal Antibodies for Treating Hospitalized Patients With COVID-19

Clinical Thought
My take on the potential utility of casirivimab plus imdevimab for hospitalized patients with COVID-19 who have higher viral burden and delayed antibody responses.

Released: August 03, 2021

Expiration: August 02, 2022

Share

Faculty

Arthur Kim

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD, has no relevant conflicts of interest to report.